Teva Reports Third Quarter 2016 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. FIS
4. BROS
5. QCOM
6. EXPE
7. PAYC
8. CPAY
9. RPD
10. MNTN

Go back to Teva Reports Third Quarter 2016 Results

Teva Pharma (TEVA): Concerns on Generics Overdone - Guggenheim

November 15, 2016 10:26 AM EST

Guggenheim analyst Louise Chen reiterated a Buy rating and $80 price target on Teva Pharma (NYSE: TEVA) following results. The analyst said concerns that generic sales are disappearing are overdone.

Chen commented, "TEVA reported a 3Q16 beat, underscoring our belief that its execution is still... More

Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook

November 15, 2016 7:01 AM EST

(Updated - November 15, 2016 7:05 AM EST)

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $5.56 billion versus the consensus estimate of $5.75 billion.

The company sees Q3 EPS of $1.34 - $1.44 with... More